Portal de Periódicos da CAPES

Efficacy and Safety of 1‐Month Postpartum Zidovudine‐Didanosine to Prevent HIV‐Resistance Mutations after Intrapartum Single‐Dose Nevirapine

2010; Oxford University Press; Volume: 50; Issue: 6 Linguagem: Inglês

10.1086/650745

1537-6591

Marc Lallemant, Nicole Ngo‐Giang‐Huong, Gonzague Jourdain, Patrinee Traisaithit, Tim R. Cressey, Intira Jeannie Collins, Tapnarong Jarupanich, Thammanoon Sukhumanant, Jullapong Achalapong, Prapan Sabsanong, M. Tiv, Narong Winiyakul, Surabon Ariyadej, Annop Kanjanasing, Janyaporn Ratanakosol, Jittapol Hemvuttiphan, Karun Kengsakul, Wiroj Wannapira, Veerachai Sittipiyasakul, Witaya Pornkitprasarn, Prateung Liampongsabuddhi, Kenneth McIntosh, Russell B. Van Dyke, Lisa M. Frenkel, Suporn Koetsawang, Sophie Le Cœur, Siripon Kanchana,

HIV Research and Treatment

Intrapartum single-dose nevirapine plus third trimester maternal and infant zidovudine are essential components of programs to prevent mother-to-child transmission of human immunodeficiency virus (HIV) in resource-limited settings. The persistence of nevirapine in the plasma for 3 weeks postpartum risks selection of resistance mutations to nonnucleoside reverse-transcriptase inhibitors (NNRTIs). We hypothesized that a 1-month zidovudine-didanosine course initiated at the same time as single-dose nevirapine (sdNVP) would prevent the selection of nevirapine-resistance mutations.